secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019094
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q1 2022 net loss of $7.0M; secures $100.5M private placement
------------------------------------------------------------------------------

- Net loss for Q1 2022 was $7.0M, compared to $7.8M in Q1 2021.
- Cash and cash equivalents at March 31, 2022 were $33.8M; subsequently received $100.5M gross proceeds from April private placement.
- Research and development expenses increased to $8.5M from $4.8M, driven by clinical trial costs.
- ENLIGHTEN Phase 3 program for LYR-210 enrollment ongoing; ENLIGHTEN II initiation targeted mid-2022.
- BEACON Phase 2 trial for LYR-220 first patient treated in Australia; Part 2 expected in U.S. in Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022019094/0001564590-22-019094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000156459022019094/lyra-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer